Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2022, with a specific reporting date of March 9, 2022. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $39.46 per ADS.
- Total Volume: 1,400.632 ADSs (comprising 1,187.632 notional ADSs and 213 ADSs).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses two acquisition transactions executed on March 7, 2022, on the New York Stock Exchange (XNYS).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of an executive's participation in company savings plans.
Important Facts for Investors
- Executive Involved: Dr. H. Barron, Chief Scientific Officer and President, R&D.
- Transaction Type: Acquisitions of ADSs within the GSK Executive Supplemental Savings Plan and the GSK 401(k) Plan.
- Transaction Date: March 7, 2022.
- Market Price: Transactions occurred at $39.46 per ADS.
- Scope: This filing does not contain quarterly or annual financial results.